Pluristem Therapeutics Company Profile (NASDAQ:PSTI)

Analyst Ratings

Consensus Ratings for Pluristem Therapeutics (NASDAQ:PSTI) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.63 (206.29% upside)

Analysts' Ratings History for Pluristem Therapeutics (NASDAQ:PSTI)
Show:
DateFirmActionRatingPrice TargetActions
7/27/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016HC WainwrightReiterated RatingBuy$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2015Needham & Company LLCLower Price TargetBuy$5.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/22/2014Oppenheimer Holdings Inc.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2014Jefferies GroupLower Price TargetHold$3.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Pluristem Therapeutics (NASDAQ:PSTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
2/10/2016        
11/24/2014($0.13)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/6/2014($0.13)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/11/2014($0.15)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/22/2014($0.14)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pluristem Therapeutics (NASDAQ:PSTI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.10)($0.10)($0.10)
Q2 20161($0.10)($0.10)($0.10)
Q4 20161($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pluristem Therapeutics (NASDAQ:PSTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/22/2016Zami AbermanCEOBuy5,000$1.33$6,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2016Yaky YanayCFOBuy5,000$1.20$6,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Yaky YanayCFOBuy15,000$0.95$14,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/15/2016Doron ShorrerDirectorBuy12,346$0.81$10,000.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Yaky YanayCFOBuy5,000$0.83$4,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2016Israel Ben-YoramDirectorBuy10,000$0.79$7,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2016Zami AbermanCEOBuy31,000$0.80$24,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Yaky YanayCFOBuy10,000$1.52$15,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Zami AbermanCEOBuy9,900$1.49$14,751.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Israel Ben-YoramDirectorSell30,000$2.10$63,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Yaky YanayCFOBuy10,000$2.11$21,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Zami AbermanCEOBuy25,500$2.11$53,805.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2015Yaky YanayCFOBuy10,000$2.12$21,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Zami AbermanCEOBuy25,000$2.11$52,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Yaky YanayCOOBuy11,000$2.62$28,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Zami AbermanCEOBuy13,000$2.64$34,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Yaky YanayCOOBuy11,000$2.95$32,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Zami AbermanCEOBuy5,000$2.92$14,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2014Zami AbermanCEOBuy5,000$2.96$14,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Israel Ben-YoramDirectorBuy5,000$2.82$14,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Boaz Gur-LavieCFOBuy3,478$2.84$9,877.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Yaky YanayCOOBuy10,000$2.85$28,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Zami AbermanCEOBuy15,000$2.80$42,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Mark GermainDirectorSell43,215$3.12$134,830.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pluristem Therapeutics (NASDAQ:PSTI)
DateHeadline
07/27/16 08:59 AMPluristem Therapeutics Inc. (NASDAQ:PSTI) Updates On U.S. FDA Study In Hematologic Indication - Journal Transcript
07/27/16 08:59 AMPluristem Therapeutics Inc. (NASDAQ:PSTI) Stock Gathers Momentum On Positive Clinical Trials Results - Journal Transcript
07/27/16 06:38 AMPluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip Fracture - [at noodls] - Clinical Advisory Board of leading orthopedic specialists and experts in rehabilitation met to discuss the design of the Phase III study prior to submission of the protocol to the FDA Pluristem has already ...
07/27/16 06:01 AM7:01 am Pluristem Therapeutics intends to conduct a Phase III trial assessing its PLX-PAD cells in recovery following surgery for femoral neck fracture -
07/22/16 08:53 AMPluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorted Shares Decreased By 4.32% - Press Telegraph
07/20/16 08:49 AMPluristem Therapeutics (PSTI) Announces Participation in Radiation Injury Treatment Network's Meeting - StreetInsider.com
07/20/16 06:00 AMPluristem Participates in Radiation Injury Treatment Network Conference Co-sponsored by National Institutes of Health’s NIAID - [GlobeNewswire] - HAIFA, Israel, July 20, 2016-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced its participation in the Radiation Injury Treatment Network’ s meeting ...
07/19/16 01:48 PMPluristem Therapeutics, Inc. – Value Analysis (NASDAQ:PSTI) : July 19, 2016 -
07/18/16 06:03 PMPluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorts Decreased by 11.39% After Short Covering - Consumer Eagle
07/18/16 06:03 PMPluristem Therapeutics, Inc. (NASDAQ:PSTI) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/18/16 06:03 PMIs $6 Price Target Attainable For Pluristem Therapeutics, Inc. (NASDAQ:PSTI)? - Investor Newswire
07/18/16 06:03 PMNext Weeks Broker Price Targets For Pluristem Therapeutics, Inc. (PSTI) - Fiscal Standard
07/16/16 09:14 AMBroker Outlook For Pluristem Therapeutics, Inc. (PSTI) - Fiscal Standard
07/15/16 11:07 AMCrowd Rating and Earnings Recap for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Telanagana Press
07/13/16 06:22 PMPluristem Therapeutics Inc (NASDAQ:PSTI) Institutional Investor Sentiment Analysis - Consumer Eagle
07/13/16 08:52 AMStrong Sell Calls For Pluristem Therapeutics, Inc. (NASDAQ:PSTI) At 0 - Investor Newswire
07/13/16 08:52 AMOption Market: Pluristem Therapeutics Inc Risk Hits An Extreme High - CML News
07/13/16 02:02 AMPluristem Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PSTI-US : July 13, 2016 -
07/11/16 10:37 AMPluristem Advances its U.S. FDA Trial in Hematologic Indication
07/11/16 08:45 AMPluristem Advances Phase I Study Of PLX-R18 Cells To Treat Insufficient Hematologic - Pluristem Therapeutics Inc. (NASDAQ: PSTI) revealed that it advanced its Phase I study of PLX-R18 cells to treat insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT) by contracting with a leading global clinical research organization (CRO). Pluristem said the trial got the FDA clearance earlier this year and enrollment was planned to commence in the coming months. The multi-center, open-label, dose-escalating Phase I study would assess the safety of ...Full story available on Benzinga.com
07/09/16 05:21 PMRisky Sectors Produce Market Gains: Biotech & Healthcare Lead Pluristem Therapeutics Inc. (NASDAQ:PSTI), OXIS ... - Traders350
07/07/16 06:00 PMPluristem Therapeutics Inc. : Jobs Growth Spurs Boon to Stocks on Thursday
07/06/16 06:13 PMPluristem Therapeutics, Inc. (NASDAQ:PSTI) Expected to Reach Highs Of $6 - Investor Newswire
07/06/16 06:13 PMCan Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Improve on the Earnings Front? - Engelwood Daily
07/06/16 06:13 PMStock Rating Watch and Earnings Insight for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Press Telegraph
07/06/16 06:13 PMBroker Outlook For The Week Ahead Pluristem Therapeutics, Inc. (PSTI) - Fiscal Standard
07/05/16 08:00 AMStonegate Capital Partners Initiates Coverage on Pluristem Therapeutics, Inc. - [Accesswire] - DALLAS, TX / ACCESSWIRE / July 5, 2016 / Stonegate Capital Partners initiates research coverage on Pluristem Therapeutics, Inc. (NASDAQ-CM: PSTI). Company Description Founded in 2001, Pluristem Therapeutics, ...
07/02/16 08:41 AMPluristem Therapeutics Incorporated (NASDAQ:PSTI) Short Interest Decreased By 11.39% - Engelwood Daily
06/30/16 08:48 AMPluristem Therapeutics, Inc. (NASDAQ:PSTI) Company Rating and Target Watch - Telanagana Press
06/29/16 05:52 PMPluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorts Decreased by 11.39% After Short Covering - Press Telegraph
06/29/16 05:52 PMStrong Sell Calls Recommendations For Pluristem Therapeutics, Inc. (NASDAQ:PSTI) At 0 - Investor Newswire
06/23/16 06:34 PMPluristem Therapeutics, (NASDAQ:PSTI) presents positive data from preclinical : Canadian Solar (NASDAQ:CSIQ ... - KC Register
06/23/16 06:34 PMWednesday's Market Insights: Tesla Motors Inc (TSLA), SolarCity Corp (SCTY), Pluristem Therapeutics Inc. (PSTI ... - Smarter Analyst
06/23/16 06:34 PMPluristem Therapeutics Inc. (NASDAQ:PSTI) Nails Phase 2 Clinical Trial With PLX-PAD - Scibility Media
06/23/16 06:34 PMPluristem Therapeutics (PSTI) Catches Eye: Stock Up 11.6% - Nasdaq
06/23/16 07:15 AMPluristem Therapeutics (PSTI) Catches Eye: Stock Up 11.6% -
06/22/16 10:42 AMPluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy
06/22/16 10:42 AMPluristem Therapeutics (PSTI) Announces Positive PLX-PAD Cells Preclinical Data in DMD
06/02/16 08:57 AMBuy, Sell Or Hold Rating For Pluristem Therapeutics, Inc. (PSTI)? - Share Trading News - Buy, Sell Or Hold Rating For Pluristem Therapeutics, Inc. (PSTI)?Share Trading News12/31/2015 – Pluristem Therapeutics, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 6 price target on the stock. 12/22/2015 – Pluristem Therapeutics, Inc. had its “buy” rating reiterated by analysts ...and more »
05/31/16 03:13 PMPLURISTEM THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
05/29/16 10:46 PMStock Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - HNN - Stock Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI)HNNInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI). Covering ...
05/25/16 10:54 PMInsiders Are Gradually Buying Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Insiders Are Gradually Buying Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Pluristem Therapeutics, Inc. (NASDAQ:PSTI) have increased their position in the stock by 1.88% over the past 6 months. Insiders now own 6.30% of total outstanding shares. There are both legal and illegal ...and more »
05/25/16 10:54 PMPluristem Therapeutics, Inc. (PSTI) Updated Broker Price Targets - Share Trading News - Pluristem Therapeutics, Inc. (PSTI) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Pluristem Therapeutics, Inc. (PSTI). The latest reports which are currently in issue on Wednesday 25th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
05/24/16 10:59 PMEarnings Review and Stock Rundown for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Earnings Review and Stock Rundown for Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Pluristem Therapeutics, Inc. (NASDAQ:PSTI ...and more »
05/23/16 10:47 AMStock Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Stock Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI). Covering ...and more »
05/22/16 05:15 PMAfter Last Week What Do Analysts Think Of Pluristem Therapeutics, Inc. (PSTI) - Share Trading News - After Last Week What Do Analysts Think Of Pluristem Therapeutics, Inc. (PSTI)Share Trading News09/15/2014 – Pluristem Therapeutics, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 3 price target on the stock. The share price of Pluristem Therapeutics, Inc. (PSTI) was up +5.67% during the last trading session ...and more »
05/21/16 09:14 AMAlpha One Assigns Impact Score Of 0 To Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Investor Newswire - Alpha One Assigns Impact Score Of 0 To Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Investor NewswireAlpha One analyzed the various web articles published on Pluristem Therapeutics, Inc. (NASDAQ:PSTI), and thereafter it gave company a daily sentiment score of 0.56. The entity designs algorithm based assessment to known stock sentiment on stock after ...and more »
05/18/16 09:59 AMShare Recap and Earnings Focus on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Share Recap and Earnings Focus on Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Pluristem Therapeutics, Inc.and more »
05/16/16 05:31 PMPluristem Therapeutics (PSTI) Announces Completion of PLX-PAD Phase 2 Enrollment - StreetInsider.com - Pluristem Therapeutics (PSTI) Announces Completion of PLX-PAD Phase 2 EnrollmentStreetInsider.comPluristem Therapeutics Inc. (Nasdaq: PSTI) announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded, PLX-PAD, cells for the treatment of intermittent claudication (IC), a peripheral artery ...Pluristem Therapeutics Completes Enrollment in Phase II Intermittent Claudication Trial (NASDAQ:PSTI)Sonoran Weekly Reviewall 3 news articles »
05/16/16 10:51 AMConsensus Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Wall Street Hints and News - Consensus Rating Review for Pluristem Therapeutics, Inc. (NASDAQ:PSTI)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »

Social

About Pluristem Therapeutics

Pluristem Therapeutics logoPluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular, orthopedic, pulmonary, hematological and women's health diseases. The Company is focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's placenta expanded (PLX) cells are intended to function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals that are generated by the patient's own body. PLX cells are grown using its three-dimensional (3D), micro environment technology, which produces a product that requires no tissue matching prior to administration. Its PLX products are in clinical-stage development for multiple indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PSTI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.51
  • 50 Day Moving Average: $1.41
  • 200 Day Moving Average: $1.39
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $121.04M
  • Beta: 0.63
  • Current Year EPS Consensus Estimate: $-0.3 EPS
  • Next Year EPS Consensus Estimate: $-0.32 EPS
Additional Links:
Pluristem Therapeutics (NASDAQ:PSTI) Chart for Thursday, July, 28, 2016